MedTrace Logo

Acute Kidney Injury in Severe Trauma

NCT03433079 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2018-02-14

No results posted yet for this study

Summary

Acute kidney injury (AKI) represents a serious complication following severe injury associated with adverse outcome. Main goals of the presented study were to define the incidence of AKI and to evaluate the validity of AKI biomarker neutrophil gelatinase-associated lipocalin (NGAL) in AKI prediction in severely injured patients. Secondary goals were to determine the time-dependent role of injury-related tissue hypoxia, systemic inflammatory response, and rhabdomyolysis in the pathophysiology of AKI.

Conditions

Interventions

DIAGNOSTIC_TEST

Neutrophil gelatinase-associated lipocalin (NGAL)

Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.

DIAGNOSTIC_TEST

Arterial lactate

Arterial lactate level was assessed in all patients.

DIAGNOSTIC_TEST

Interleukin-6 (IL-6)

The level of interleukin-6 was assessed in all patients.

DIAGNOSTIC_TEST

Procalcitonin (PCT)

The level of procalcitonin (PCT) was assessed in all patients.

DIAGNOSTIC_TEST

Myoglobin

The level of myoglobin was assessed in all patients.

Sponsors & Collaborators

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Peter Sklienka, MD · University Hospital Ostrava

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-01
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433079 on ClinicalTrials.gov